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Abstract
Background: The onset and the development of neoplastic disease may be influenced by many physiological, 
biological and immunological factors. The nervous, endocrine and immune system might act as an integrated unit to 
mantain body defense against this pathological process and reciprocal influences have been evidenced among 
hypothalamus, pituitary, thyroid, adrenal, pineal gland and immune system. In this study we evaluated differences 
among healthy subjects and subjects suffering from lung cancer in the 24-hour secretory profile of melatonin, cortisol, 
TRH, TSH, FT4, GH, IGF-1 and IL-2 and circadian variations of lymphocyte subpopulations. 
Methods: In ten healthy male volunteers (age range 45-66) and ten male patients with untreated non small cell lung 
cancer (age range 46-65) we measured melatonin, cortisol, TRH, TSH, FT4, GH, IGF-1 and IL-2 serum levels and 
percentages of lymphocyte subpopulations on blood samples collected every four hours for 24 hours. One-way 
ANOVA between the timepoints for each variable and each group was performed to look for a time-effect, the 
presence of circadian rhythmicity was evaluated, MESOR, amplitude and acrophase values, mean diurnal levels and 
mean nocturnal levels were compared.
Results: A clear circadian rhythm was validated in the control group for hormone serum level and for lymphocyte 
subsets variation. Melatonin, TRH, TSH, GH, CD3, CD4, HLA-DR, CD20 and CD25 expressing cells presented circadian 
rhythmicity with acrophase during the night. Cortisol, CD8, CD8bright, CD8dim, CD16, TcRδ1 and δTcS1 presented 
circadian rhythmicity with acrophase in the morning/at noon. FT4, IGF-1 and IL-2 variation did not show circadian 
rhythmicity. In lung cancer patients cortisol, TRH, TSH and GH serum level and all the lymphocyte subsubsets variation 
(except for CD4) showed loss of circadian rhythmicity. MESOR of cortisol, TRH, GH, IL-2 and CD16 was increased, 
whereas MESOR of TSH, IGF-1, CD8, CD8bright, TcRδ1 and δTcS1 was decreased in cancer patients. The melatonin/
cortisol mean nocturnal level ratio was decreased in cancer patients.
Conclusion: The altered secretion and loss of circadian rhythmicity of many studied factors observed in the subjects 
suffering from neoplastic disease may be expression of gradual alteration of the integrated function of the neuro-
immune-endocrine system
Background
There are close relations between endocrine, nervous and
immune system. Cortisol has a well recognized influence
on immune function, inducing significant immunosup-
pression, characterized by the reduced cellular and
humoral response of monocytes and B and T lympho-
cytes [1]. Melatonin, hormone secreted by the pineal
gland, is able to influence the secretion of many endo-
crine glands, modulates the function of the immune sys-
tem, shows antioxidative and oncostatic property and its
production is under the control of the nervous system [2-
5]. The pineal hormone directly stimulates activated
helper T lymphocytes and plays an immunomodulatory
role by opioid peptides [6] and by a thyroid-independent
influence on the thymic function mediated by thyrotro-
pin-releasing hormone (TRH) and thyroid-stimulating
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hormone (TSH) [7]. The insulin like growth factor (IGF)-
1 is a potent mitogen for many cancer cell lines and the
stimulation of IGF-1 receptor is necessary for prolifera-
tion of many cells in vivo and in vitro, often in conjunc-
tion with other growth factors [8]. Besides, recent studies
have put in evidence that growth hormone (GH) and
IGF-1 have an important role in stimulating lymphocyte
production and function [9]. Abnormalities in hormone
serum levels and in the proportions of various lympho-
c y t e  s u b p o p u l a t i o n s  h a v e  b e e n  f o u n d  i n  a  n u m b e r  o f
tumors [10]. The purpose of this study was to evaluate
the 24-hour profiles of lymphocyte subsets and neuro-
endocrine hormones with the aim to highlight alterations
in patients suffering from lung cancer.
Methods
The study was approved by the local Scientific and Ethi-
cal Committee (approval number MGRL001 approval
date 6/4/2008). After obtainment of informed consent
peripheral blood samples were collected at intervals of
four hours for 24 hours starting at 06:00 h from ten
healthy subjects (HS, mean age ± s.e. 57.2 ± 2.7, range 45-
66) and from ten patients with untreated non small cell
lung cancer (CP, mean age ± s.e. 56.6 ± 0.2, range 46-65).
Inclusion criteria for healthy subjects were sex (male), age
(<80 years), BMI (>25 and <30), normal physical activity
level, no psychiatric disorder, no alcohol intake, no
chronic conditions, normal blood pressure level. In all
control subjects healthy status was assessed by medical
history and physical examination, basal screening blood
and urine test, ECG, chest X ray, upper and lower abdom-
inal ultrasound scan. Inclusion criteria for subjects suf-
fering from lung cancer were sex (male), age (<80 years),
BMI (>25 and <30), normal physical activity level, perfor-
mance status >80% by Karnofsky performance status
scale or <2 by ECOG score, no psychiatric disorder , no
alcohol intake, no chronic conditions, normal blood pres-
sure level, tumor cell type (non small cell lung cancer ,
NSCLC) and the extent of the tumor was evaluated by
clinical examination, bronchoscopy, computed tomogra-
phy (CT) of the brain, chest, upper abdomen and ultra-
sonography of the liver. There were 3 cases of squamous
cell carcinoma and 7 of adenocarcinoma. The pathologi-
cal diagnosis was based on light microscopy according to
the WHO classification. Tumors were staged according to
the TNM classification of the International Union
Against Cancer staging system after reviewing the clini-
cal, radiologic, and pathologic data. The numbers of pT1,
pT2, and pT3-4 cases were 3, 5, and 2 respectively. All 10
cases showed metastasis to regional lymph nodes.
Regarding stage, the numbers of stage I, II, and III cases
were 2, 5, and 3 respectively. The groups were matched
closely to avoid sex, body mass index and seasonality of
sampling related bias and all subjects were submitted to
the same social routine, with identical mealtimes and
sleep/wakefulness rhythm in the week preceding the
sampling (lights on at 07:00 a.m. and lights out at 10:00
p.m., thereby supplying the subjects with 15 hours of light
and 9 hours of darkness per day, 15:9 L:D). During the
overnight sampling period a dim blue light (<100 lux) was
used. In each blood sample we measured melatonin, cor-
tisol, TRH, TSH, free thyroxine, GH, IGF-1 and IL-2.
Blood was centrifuged immediately after collection and
frozen at -20°C for later determination. All samples were
analyzed in duplicate in a single assay; the intrassay and
interassay coefficients of variation were below 13% and
16% respectively for melatonin, 10% and 9% for cortisol,
5% and 6% for TRH, 8% and 7% for TSH, 4% and 6% for
FT4, 5% and 3% for GH, 3% and 8% for IGF-1, 5% and 7%
for IL-2. Standard curves were run with every assay and
the experimental values were derived from the curves.
We measured melatonin by radioimmunoassay (Mela-
tonin Radioimmunoassay Kit, Nichols Institute Diagnos-
tics), cortisol by polarized light immuno-fluorescence
assay (Cortisol TDx/TDxFLx, Abbott Laboratories), TRH
by radioimmunoassay ("Frederic Joliot-Curie" National
Research Institute for Radiobiology and Radiohygiene,
Budapest, Hungary), TSH by immunoenzymatic assay
(Enzymun-Test TSH, Boehringer Mannheim Immunodi-
agnostics), FT4 by immunoenzymatic assay (Enzymun-
Test FT4, Boehringer Mannheim Immunodiagnostics),
GH by immunoenzymometric assay (AIA-PACK HGH,
Tosoh, Japan) and IGF-1 by radioisotopic assay (IGF-1
100T Kit, Nichols Institute Diagnostics), IL-2 by immu-
noenzymatic assay (IL-2 EIA, Technogenetics). In each
blood sample we analyzed lymphocyte subpopulations
(CD3, CD4, CD8, CD8 bright, CD8 dim, CD16, CD20,
CD25, HLA-DR, TcRδ1, δTcS1) on peripheral blood anti-
coagulated with sodium ethylenediamine tetraacetic acid
(EDTA). Analyses of lymphocyte subpopulations were
performed on unfixed cell preparations with a fluores-
cence activated cell sorter (FACScan, Becton-Dickinson
FACS Systems, Sunnyvale, California) and a panel of
monoclonal antibodies (mAbs) to lymphocyte surface
antigens (Ortho Diagnostic Systems: OKT3, OKT4,
OKT8, OK-NK, OKB20, OKT26a, OK-DR; Thermo-Sci-
entific, Rockford, IL, USA: TcRδ1 and δTcS1). mAbs were
directly conjugated with phycoerythrin (PE) and to fluo-
rescein isothiocyanate (FITC).  10 μl mAbs were added to
100 ml EDTA blood in Trucount tubes (BD Biosciences,
San Jose, CA). After a 15-min incubation at room tem-
perature the erythrocytes were disintegrated and after
centrifugation the supernatants were washed with PBS.
Non-lymphocytic cells contaminating the preparations
were excluded from analysis using scatter gates set on the
90° light scatter profile. At least 10000 cells were acquired
on the FACScan. Absolute counts of T cell subsets wereMazzoccoli et al. BMC Cancer 2010, 10:314
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calculated based on the proportion of the respective T
cell subpopulation and on absolute counts obtained by
the procedure. The number of fluorescent cells was
expressed as a percentage of the total lymphocytes.
Statistical analysis
Statistical evaluation of hormone serum levels and lym-
phocyte subpopulation values was performed by non-
inferential descriptive biometric analyses, including one-
way ANOVA performed between the timepoints for each
variable and each group on original data and on data
transformed as % of their individual 24 h mean to look for
a time-effect, Student's t test and Mann-Whitney rank
sum test, where appropriate, on MESOR, amplitude and
acrophase values and on mean diurnal and nocturnal lev-
els; a p value ≤ 0.05 was considered significant. The data
were also analyzed by an inferential temporal descriptive
biometric analysis using the methods named Single
Cosinor and Population Mean Cosinor, based on a least-
squares fit of a cosine curve to individual and grouped
time series data, testing the occurrence of a 24 h rhythm
(whether the zero-amplitude assumption is rejected at a
probability level p ≤ 0.05) and quantifying the parameters
MESOR, Amplitude and Acrophase of the rhythm.
MESOR is the acronym for Midline Estimating Statistic
of Rhythm and defines the rhythm-determined average.
Amplitude is the measure of one half the extent of rhyth-
mic change in a cycle estimated by the function used to
approximate the rhythm. Acrophase, measure of timing,
is the phase angle of the crest time in the function appro-
priately approximating a rhythm, in relation to the speci-
fied reference timepoint. Chronobiologic analysis was
performed with Cosinor 2.2. ANOVA, Student's t  test
and Mann-Whitney rank sum test were performed with
SigmaPlot11.0 [11].
Results
In the healthy subjects ANOVA showed a time effect for
cortisol, melatonin, TRH, TSH, GH, CD3, CD4, CD8,
CD8bright , CD8dim , CD16, TcRδ1 and δTcS1 and a clear
circadian rhythm was validated for the variation of hor-
m o n e  s e ru m  l ev e l s  a n d  o f  l ym p h ocyt e  s u b s e t  pe r c e n t -
ages: melatonin, TRH, TSH, GH, CD3 (total T cells), CD4
(T helper/inducer subset), HLA-DR (B cells and activated
T cells), CD20 (total B cells) and CD25 (T activated lym-
phocytes with expression of the α chain of IL-2 receptor)
presented circadian rhythmicity with nocturnal acro-
phase. Cortisol, CD8 (T suppressor/cytotoxic subset),
CD8bright (T suppressor subset), CD8dim (T cytotoxic sub-
set), CD16 (natural killer cells), TcRδ1 (epitope of the
constant domain of δ chain of TCR) and δTcS1 (epitope
of the variable domain of δ chain of TCR) presented cir-
cadian rhythmicity with diurnal acrophase. FT4, IGF-1
and IL-2 variation did not show circadian rhythmicity. In
lung cancer patients ANOVA showed a time effect for
cortisol, melatonin, TSH, CD4, CD16, CD25, TcRδ1 and
IL2. Cortisol, TRH, TSH and GH serum level and all the
lymphocyte subsubsets variation (except for CD4)
showed loss of circadian rhythmicity. MESOR of cortisol,
TRH, GH, IL-2 and CD16 was increased in cancer
patients, whereas MESOR of TSH, IGF-1, CD8, CD8bright,
TcRδ1 and δTcS1 was decreased in cancer patients (Fig-
ure 1, figure 2 and figure 3).
When we compared mean diurnal levels (mean of
06:00h-10:00h-14:00h) GH (p < 0.001) and CD16 (p <
0.01) levels were higher in cancer patients, whereas IGF1
(p < 0.001), CD8 (p = 0.03) and CD8bright (p = 0.001) levels
were lower in cancer patients. When we compared mean
nocturnal levels (mean of 18:00h-22:00h-02:00h) cortisol
(p = 0.02), TRH (p = 0.03), GH (p < 0.01), CD16 (p <
0.0001) and CD25 (p = 0.03) levels were higher in cancer
patients, whereas melatonin (p = 0.04), TSH (p = 0.02),
IGF-1 (p < 0.0001), CD8 (p = 0.01), CD8bright (p = 0.001),
CD20 (p = 0.03), TcRδ1 (p = 0.001) and δTcS1 (p = 0.02)
levels were lower in cancer patients. The melatonin/corti-
sol mean nocturnal level ratio was decreased in cancer
patients (p = 0.01)
Table 1 shows chronobiological data derived from best
fitting sine curves (fitted period:24 hours = 360°), F and p
value from ANOVA performed between the timepoints
for each variable and p value from Student's t test and
Mann-Whitney rank sum test, where appropriate, on
MESOR, amplitude and acrophase values between
healthy subjects and lung cancer patients. Figure 1 and 2
show x-y plot depicting 24-hour time qualified profiles of
lymphocyte subset percentages and hormone serum lev-
els.
Discussion and Conclusion
Body homeostasis is maintained by a perfect integration
among the nervous, endocrine and immune system
involving different glands and organs and guided by a
spatio-temporal sequence of tissue-specific events, hor-
mone and cyto-chemokine/receptor interaction and
modulation processes. The pineal gland is innervated by
post-ganglionic nervous fibers coming from the superior
cervical ganglion, that receives fibers from the suprachi-
asmatic nucleus of hypotalamus, innervated by the retin-
ohypothalamic tract. Changes in lighting condition
influence activity of the retino-hypothalamic-pineal sys-
tem, with inhibiting effect on melatonin production, con-
trolled also by an endogenous free-running pacemaker
located in the suprachiasmatic nucleus [12]. The mela-
tonin mediated photoperiodic message is a fundamental
cue for the circadian and seasonal coordination of biolog-
ical functions. Melatonin plays a role of immunomodula-
tion by opiatergic ways and stimulates activated helper T
lymphocytes to produce opioid agonists and cytokinesMazzoccoli et al. BMC Cancer 2010, 10:314
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(IL-2 and IL-4) [13,14]. The immunomodulatory role of
melatonin may also be exerted by an influence on the thy-
mic function mediated by TRH and TSH, able to counter-
act in experimental conditions thymic involution induced
by prednisolone (this effect seems to be thyroid-indepen-
dent and not correlated to thyroxine levels) [15].
TRH and TSH secretion changes with circadian period-
icity and nightly peak hormone serum levels have been
described. Thyroxine (T4) and triiodothyronine (T3)
serum levels present minor changes during a 24-h period,
their fluctuations are shortlived and diurnal variations in
hormone levels can be demonstrated in most, but not in
all instances. In our control subjects TRH and TSH blood
levels show circadian variations with higher levels during
the night, whereas thyroid hormone levels do not change
with circadian rhythmicity. Melatonin may regulate the
Figure 1 Nyctohemeral variation of hormone serum levels. x-y plot showing 24-hour time qualified profiles of cortisol, melatonin, TRH, TSH, free 
thyroxine, GH and IGF 1 expressed as mean ± s.e. calculated on single time point values from ten healthy subjects and ten patients suffering from non 
small cell lung cancer. Cubic regression function data interpolation represented as best fit solid line superimposed on the raw data (dotted line).Mazzoccoli et al. BMC Cancer 2010, 10:314
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response of thyroid to hypothalamic-pituitary axis stimu-
lation, playing a modulatory action on hypothalamic-
pituitary-thyroid axis and functioning as a servo-mecha-
nism that diminishes or increases responses when stimuli
are respectively too strong or too low [16,17]. This phe-
nomenon, called feed-sideward, takes part also in the
interaction among the pineal gland and the hypotha-
lamic-pituitary-adrenal axis [18].
GH and IGF-1 have been recognized as stimulators of
lymphopoiesis and immune function. IGF-1 is one of the
most important growth factors for normal cell prolifera-
tion and several tumor cell lines have recently appeared
to be also stimulated by this mitogen: it acts as an endo-
crine hormone via the blood and as paracrine and auto-
crine growth factor locally. GH stimulates the
biosynthesis of IGF-1 in liver and in other organs and tis-
Figure 2 Nyctohemeral variation of lymphocyte subpopulations. x-y plot showing 24-hour time qualified profiles of lymphocyte subset percent-
ages (CD3, CD4, CD8, CD8bright, CD8dim, CD16, CD20, CD25) expressed as mean ± s.e. calculated on single time point values from ten healthy subjects 
and ten patients suffering from non small cell lung cancer. Cubic regression function data interpolation represented as best fit solid line superimposed 
on the raw data (dotted line).Mazzoccoli et al. BMC Cancer 2010, 10:314
http://www.biomedcentral.com/1471-2407/10/314
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sues and an autocrine or paracrine GH/IGF-1 system
have been evidenced in lymphoid tissues, capable of
influencing lymphopoiesis and immune function [19-21].
Neoplastic diseases are characterized by an altered pat-
tern of hormonal secretion, with changes that may be
qualitative (loss of circadian rhythmicity) and/or quanti-
tative (increase or decrease of serum levels) as variously
described by many scientific studies [22-25].
Immune responses show temporal variations, related to
circadian changes of total lymphocytes and specific lym-
phocyte subsets in the peripheral blood, of antibodies
and cell mediated immune responses, with an inverse
relationship to plasma cortisol concentration [26-30].
Cortisol has a well recognized influence on immune
function, inducing significant immunosuppression, char-
acterized by the reduced cellular and humoral response
of monocytes and B and T lymphocytes [31]. There are
different circadian variations of the total number of cir-
culating immune cells and of specific lymphocyte sub-
populations [32,33]. As evidenced in our healthy control
subjects, circulating T and B cell percentages levels
change with circadian rhythmicity in antiphase with the
rhythm of cortisol and this rhythm of variation is recog-
nizable for the changes of total T cells, T helper/inducer
subset, B cells and activated T cells, total B cells, T acti-
vated lymphocytes with expression of the α chain of IL-2
receptor. The levels of T suppressor/cytotoxic lympho-
cytes, natural killer cells and γδTCR expressing cells are
higher in the morning. Immune system plays an impor-
tant role in the defense against neoplastic disease: there
exists an effective T-cell mediated immune surveillance
capable of monitoring the genetic integrity of mammalian
cells, T lymphocytes are an essential component of spe-
cific immune responses wich produce tumour rejection
and endocrine and immune alterations have been evi-
denced in cancer patients.
Data obtained in our study shows that in lung cancer
patients cortisol, TRH, TSH and GH secretion is altered
with loss of circadian rhythmicity. The disappearance of
circadian rhythm of cortisol secretion is typical of hyper-
cortisolism and adding to the reduced nocturnal mela-
tonin secretion determines in our cancer patients the
observed decrease of the melatonin/cortisol ratio. An
altered pattern of cortisol secretion (absence of circadian
rhythmicity and increased production), together with
reduced nightly melatonin secretion, may represent a
marker of neuro-endocrine system disorder [34]. The loss
of circadian rhtyhmicity of cortisol serum level variation
may be caused by an alteration of central nervous system
(CNS) regulatory mechanisms of cortisol secretion and
may be involved in a dual relationship to the melatonin
secretion pattern [35]. The pineal gland influences the
Figure 3 Nyctohemeral variation of lymphocyte subpopulations. x-y plot showing 24-hour time qualified profiles of lymphocyte subset percent-
ages (HLA-DR, TcRδ1, δTcS1) and IL-2 serum levels expressed as mean ± s.e. calculated on single time point values from ten healthy subjects and ten 
patients suffering from non small cell lung cancer. Cubic regression function data interpolation represented as best fit solid line superimposed on the 
raw data (dotted line).M
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Table 1: Chronobiological data derived from best fitting sine curves (fitted period:24 hours = 360°) and F and p value from ANOVA performed between the 
timepoints for each variable
Healthy subjects Lung cancer patients
Factor p# MESOR ± SE Amplitude ± SE Acrophase ± SE ANOVA p# MESOR ± SE Amplitude ± SE Acrophase ± SE ANOVA
Original 
Units
% of mean Original 
Units
% of mean
FpFp F pFp
Cortisol 0.027 12.52 ± 1.53 5.85 ± 1.97 08:08 ± 01:18 6.3 0.01 22.3 <0.01 0.138 17.85 ± 1.03* 4.21 ± 1.39 09:00 ± 01:32 1.1 0.41 5.1 <0.01
Melatonin 0.013 38.75 ± 5.43 26.24 ± 7.32 01:13 ± 01:15 14.2 <0.01 25.4 <0.01 0.036 33.12 ± 7.34 23.12 ± 9.94 01:28 ± 01:37 4.9 <0.01 12.3 <0.01
TRH 0.024 0.45 ± 0.09 0.04 ± 0.05 02:47 ± 01:05 0.1 0.97 4.5 0.01 0.245 0.60 ± 0.02* 0.03 ± 0.04 23:41 ± 01:48 0.3 0.35 0.5 0.46
TSH 0.020 1.38 ± 0.04 0.45 ± 0.03 23:12 ± 00:32 2.3 0.08 12.5 0.01 0.328 1.33 ± 0.09* 0.18 ± 0.08 00:05 ± 02:05 0.6 0.78 3.9 0.01
FT4 0.897 1.24 ± 0.06 0.01 ± 0.03 15:52 ± 08:08 0.3 0.95 1.4 0.15 0.377 1.33 ± 0.02 0.02 ± 0.03 18:44 ± 02:13 0.4 0.96 0.8 0.72
GH 0.039 0.38 ± 0.03 0.45 ± 0.02 00:22 ± 00:50 3.9 0.01 5.8 <0.01 0.447 1.55 ± 0.17* 0.38 ± 0.23 22:16 ± 02:36 0.5 0.61 1.3 0.23
IGF-1 0.578 221.01 ± 6.0 9.34 ± 8.12 08:28 ± 03:24 0.2 0.76 3.4 0.09 0.424 156.02 ± 1.88* 4.05 ± 2.36 02:41 ± 02:26 0.1 0.89 1.7 0.29
CD3 0.014 82.10 ± 0.31 0.98 ± 0.53 03:17 ± 22:09 0.3 0.96 2.3 0.04 0.135 83.01 ± 0.21 1.08 ± 0.25 20:49 ± 01:21 0.7 0.76 1.9 0.21
CD4 0.033 45.12 ± 0.75 3.11 ± 1.02 01:16 ± 01:17 1.5 0.36 4.0 <0.01 0.035 43.83 ± 1.27 6.13 ± 1.47 22:48 ± 00:53 2.3 0.04 6.2 0.01
CD8 0.024 29.61 ± 0.74 2.59 ± 1.04 12:48 ± 01:37 0.4 0.76 4.2 0.01 0.531 23.12 ± 0.36* 0.52 ± 0.46 11:21 ± 03:04 0.4 0.98 0.9 0.61
CD8 Bright 0.039 21.06 ± 0.54 1.35 ± 072 13:34 ± 02:04 0.6 0.84 1.4 0.04 0.597 15.21 ± 0.26* 0.42 ± 0.36 04:45 ± 03:19 0.3 0.93 0.7 0.72
CD8 Dim 0.028 9.22 ± 0.39 1.10 ± 0.49 12:37 ± 01:58 1.5 0.35 3.7 0.01 0.631 9.45 ± 0.43 0.82 ± 0.69 12:46 ± 03:40 0.6 0.62 1.2 0.39
CD16 0.015 7.89 ± 0.21 1.42 ± 0.36 13:24 ± 01:37 0.7 0.51 2.8 0.01 0.187 16.33 ± 0.41* 2.12 ± 0.37 11:16 ± 01:32 0.5 0.81 2.3 0.05
CD20 0.006 11.21 ± 0.04 1.21 ± 0.08 21:24 ± 00:21 0.4 0.98 2.3 0.09 0.129 8.73 ± 0.12 0.61 ± 0.45 02:21 ± 01:16 0.3 0.89 1.0 0.56
CD25 0.040 5.52 ± 0.12 0.44 ± 0.19 19:46 ± 01:34 0.2 0.93 2.4 0.08 0.526 7.02 ± 0.31 0.68 ± 0.32 20:12 ± 03:04 0.6 0.80 3.9 <0.01
HLA-DR 0.033 15.28 ± 0.39 0.69 ± 0.56 22:33 ± 03:21 0.6 0.67 2.2 0.07 0.893 14.02 ± 0.41 0.28 ± 0.49 18:47 ± 08:06 0.1 0.54 0.5 0.83
TcR δ 1 0.026 3.59 ± 0.11 0.41 ± 0.18 11:12 ± 01:33 0.2 0.89 3.2 0.04 0.082 2.24 ± 0.02* 0.94 ± 0.15 14:09 ± 00:22 1.2 0.39 3.6 0.01
δTcS1 0.036 1.43 ± 0.05 0.43 ± 0.06 10:52 ± 00:44 0.4 0.76 2.9 0.03 0.918 0.91 ± 0.20* 0.07 ± 0.18 14:56 ± 09:32 0.2 0.78 2.1. 0.08
IL-2 0.424 0.43 ± 0.02 0.05 ± 0.03 14:53 ± 02:32 0.2 0.98 0.3 0.94 0.627 0.52 ± 0.03* 0.02 ± 0.04 17:01 ± 03:10 0.4 0.86 1.0 0.05
Units: μg/dl for cortisol, pg/ml for melatonin, ng/ml for TRH, μU/ml for TSH, ng/dl for FT4, ng/ml for GH, ng/ml for IGF-I, percentage for lymphocyte subpopulations, IU/ml for IL-2; all parameters 
analyzed in all the subjects; Hr:Mn for acrophase; all parameters analyzed in all the subjects. # p value from an F-test of the null amplitude rejection hypothesis (for a rhythm with a chosen period 
?); * p value < 0.05 from t-test or Mann-Whitney rank sum test as indicated performed on MESOR, amplitude and acrophase valuesMazzoccoli et al. BMC Cancer 2010, 10:314
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function of the hypothalamus-hypophysis-adrenal axis,
melatonin regulates glucocorticoid receptors and adrenal
corticosteroids modulate pineal melatonin synthesis [36].
Data obtained in previous studies indicate that the pineal
function is significantly impaired in patients with altered
pattern of cortisol secretion or after the administration of
dexamethasone [37,38]. The melatonin/cortisol ratio, cal-
culated on the mean of nocturnal serum levels or on
overnight urinary cortisol and melatonin (or its metabo-
lite 6-hydroxy-melatonin-sulphate), may be a valuable
and reliable method for population and individual
screening for cancer at scheduled time intervals (for
example, at yearly interval in the general population and
at half-yearly interval or quarterly in subjects at elevated
risk for neoplastic disease). There are reciprocal and dif-
ferent influences also among melatonin and male and
female gonadal steroids and this is the reason why we
have considered only male subjects to avoid sex related
biases.
In our cancer patients GH serum levels are increased,
but the nyctohemeral pattern of secretion is lost and this
determines an unbalanced relationship between GH
secretion and IGF-1 serum levels, that are decreased.
Studies conducted on GH-deficient patients have dem-
ostrated that different time treatment schedules of GH
administration have different effects on IGF-1 serum lev-
els and the closest similarity to normal hormone and
metabolite patterns and relationships is reached by GH
injection in the evening [39]. All the patients enrolled in
our study had normal BMI, so that the low levels of serum
IGF-1 found in cancer patients should not be related to
the state of nutrition. A global disorder of the neuro-
endocrine axes has to be considered and may also explain
the increase of TRH levels and the decrease of TSH levels
observed in our cancer patients. An important causal fac-
tor may be represented by the altered time structure of
GH and TRH secretion evidenced in our lung cancer
patients, but another explanation may be represented by
hormone resistance. IL-2 serum levels are increased in
our cancer patients, maybe following immune activation
and maybe representative of a global increase of the oth-
ers cyto/chemokines that mediate inflammation [40].
The changes in the TRH/TSH axis and GH/IGF-1 axis
f u n c t i o n  i n  t h e  p a t i e n t s  s u f f e r i n g  f r o m  c a n c e r  m a y  b e
mediated by the inflammatory cytokines. Evidence from
cell culture and animal experiments suggests that inter-
leukin-1 (IL-1) and tumour necrosis factor-α (TNFα) can
cause GH resistance. Increased circulating levels of the
inflammatory cytokines and/or increased in vitro pro-
duction by peripheral blood mononuclear cells have been
reported in cancer patients. GH resistance with respect
to the stimulation of hepatic IGF1 production has been
observed in the lung cancer patients and GH resistance
has been associated with an acute-phase response. The
effects of the inflammatory cytokines are likely to be
mediated by complex paracrine pathways, rather than
'endocrine' pathways [41,42].
The neuro-endocrine-immune system function is char-
acterized by a complex time structure composed of mul-
tiple rhythms in different frequency ranges. The rhythms
of the same frequency may have the same phase or differ-
ent phases and usually show a well defined time-relation
to each other. The loss of the array of rhythms or a change
of their functional interactions may alter the organism's
time structure leading to chronodisruption and internal
desynchronization. The alteration of the organism's time
structure may lead to functional disturbances and may
impair repairing and defensive mechanisms. Cancer may
arise from chronodisruption and may worsen internal
desynchronization. A complete loss of rhythmicity or a
change of phase of the rhythms are the most frequent
alterations, but another important factor is represented
by the change of levels and amplitude of variation.
The multifrequency structrure that characterizes the
function of the immune system and the complexity of the
time qualified variations of its different components has
to be taken in consideration when we approach func-
tional evaluations, clinical interpretations and therapeuti-
cal interventions. Among the lymphocyte subsets
considered in our study, the CD8 bearing cells and in par-
ticular the T suppressor subset are diminished in lung
cancer patients [43,44]. The decrease of T suppressor
subpopulation has been observed in other types of cancer
(gastric cancer, colorectal carcinoma and urological can-
cer) [45-47] and may represent a marker of immunologi-
cal disorder. As evidenced in our study, the natural killer
cells are increased in cancer patients, whereas the expres-
sion of the constant and variable domains of δ chain of T-
cell receptor 1 is decreased and this may be an important
finding as γδTCR complex is mainly expressed at the cell
surface of cytotoxic lymphocytes, is involved in T cell
activation and activated γδ expressing cells frequently
exhibit cytotoxic activity against multiple target cell lines
including neoplastic cells [48].
The altered time structure and serum level evidenced
in our study for hypothalamic (TRH), pituitary (GH,
TSH), pineal (melatonin) and adrenal (cortisol) secretion
may be produced by and/or may increase the altered
interaction among nervous, endocrine and immune sys-
tem. Lung cancer patients show loss of circadian rhyth-
micity of all lymphocyte subpopulations studied except
for CD4. This phenomenon may impair an efficient
immune response, may be related to altered hormone
serum levels and to changes of the natural circadian
rhythmicity and may cause the loss of the physiological
timed windows of interaction among neural/endocrine
structures and immune effectors, considering also that
immune cells have hormone binding sites and hormoneMazzoccoli et al. BMC Cancer 2010, 10:314
http://www.biomedcentral.com/1471-2407/10/314
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production capability. The reduction in number of CD8
and γδTCR expressing cells in the peripheral blood may
represent a marker of immunological disorder or may fol-
low homing in pathological and neoplastic tissue as effec-
tor cells and/or regulatory cells.
In conclusion, our results have indicated that lung can-
cer is associated with disordered hormonal secretion and
anomalies of proportion and circadian variation of lym-
phocyte subsets, probably expression of impaired inte-
gration among nervous, endocrine and immune system
in front of advancing neoplastic disease. These systems
show natural patterns of circadian rhythmicity and it is
important to understand how multiple rhythms relate to
each other to maintain an internal order and how the loss
of this internal order may contribute to the beginning and
the progression of neoplasticdisease.
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